Manager × security

JOHNSON & JOHNSON NMRA holdings history

Who else holds this security? →

NEUMORA THERAPEUTICS INC · CUSIP 640979100 · CIK 200406

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, JOHNSON & JOHNSON reported 1.85M NMRA (shares), valued at $3.14M, or 0.39% of its reported non-derivative portfolio. Filed 2026-08-06.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.39%
Shares
1.85M
1,849,445
Reported value
$3.14M
USD

Shares unchanged; reported value decreased 12.82%, and weight changed -0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.39%1,849,445SEC filing ↗Filed Aug 6, 2026
Q1 20260.55%1,849,445SEC filing ↗Filed May 13, 2026
Q4 20250.60%1,849,445SEC filing ↗Filed Mar 18, 2026Amended
Q3 20250.67%1,849,445SEC filing ↗Filed Mar 18, 2026Amended
Q2 20250.42%1,849,445SEC filing ↗Filed Jul 22, 2025
Q1 20250.54%1,849,445SEC filing ↗Filed May 7, 2025
Q4 20245.08%1,849,445SEC filing ↗Filed Feb 13, 2025
Q3 20245.72%1,849,445SEC filing ↗Filed Nov 13, 2024
Q2 20244.54%1,849,445SEC filing ↗Filed Aug 9, 2024
Q1 20240.58%1,849,445SEC filing ↗Filed May 10, 2024
Q4 20230.72%1,849,445SEC filing ↗Filed Feb 14, 2024
Q3 20234.74%912,128SEC filing ↗Filed Nov 9, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20234.74%912,128$12.87MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 9, 2023
Q4 20230.72%1,849,445$31.53MShares increased 102.76%; reported value increased 145.01%, and weight changed -4.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20240.58%1,849,445$25.43MShares unchanged; reported value decreased 19.35%, and weight changed -0.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 10, 2024
Q2 20244.54%1,849,445$18.18MShares unchanged; reported value decreased 28.51%, and weight changed +3.96 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 9, 2024
Q3 20245.72%1,849,445$24.43MShares unchanged; reported value increased 34.38%, and weight changed +1.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 20245.08%1,849,445$19.60MShares unchanged; reported value decreased 19.76%, and weight changed -0.64 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2025
Q1 20250.54%1,849,445$1.85MShares unchanged; reported value decreased 90.57%, and weight changed -4.54 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 7, 2025
Q2 20250.42%1,849,445$1.40MShares unchanged; reported value decreased 24.31%, and weight changed -0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jul 22, 2025
Q3 20250.67%1,849,445$3.37MShares unchanged; reported value increased 140.45%, and weight changed +0.25 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Mar 18, 2026
Q4 20250.60%1,849,445$3.31MShares unchanged; reported value decreased 1.65%, and weight changed -0.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Mar 18, 2026
Q1 20260.55%1,849,445$3.61MShares unchanged; reported value increased 8.94%, and weight changed -0.05 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2026
Q2 20260.39%1,849,445$3.14MShares unchanged; reported value decreased 12.82%, and weight changed -0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 6, 2026
JOHNSON & JOHNSON · NEUMORA THERAPEUTICS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"200406","quarter":"2026Q2","cusip":"640979100"}

get_institutional_manager_history
{"cik":"200406","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.